Stockscreener 앱 받기
15.75
0.25%
-0.04
시장 영업 전:
16.22
0.47
+2.98%
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance
Entrada Therapeutics president & COO sells $229,953 in shares By Investing.com - Investing.com Canada
Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com
Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan - Stock Titan
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics R&D president sells $398,809 in shares By Investing.com - Investing.com UK
Entrada Therapeutics R&D president sells $398,809 in shares - Investing.com
Morgan Stanley Smith Barney files TRDA Form 144; 15,000 shares sold (TRDA) - Stock Titan
TRDA (NASDAQ: TRDA) reports 25,907 RSUs to sell; insider sold March 2026 - Stock Titan
Entrada Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month HighWhat's Next? - MarketBeat
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday - MarketBeat
Is Entrada Therapeutics (TRDA) stock showing strong momentum | Q4 2025: EPS Tops ViewsTrending Social Stocks - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Entrada Therapeutics (NASDAQ: TRDA) details 2026 proxy and equity plan changes - Stock Titan
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
TRDA (Entrada Therapeutics) reports narrower Q4 2025 loss than expected, shares edge lower on steep revenue decline.Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a Potential 52.97% Upside in the Biotech Sector - DirectorsTalk Interviews
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week HighShould You Buy? - MarketBeat
Sell Signal: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Buyback Activity & Long-Term Safe Investment Plans - baoquankhu1.vn
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing - Stock Traders Daily
Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Investment Report: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
TRDA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor Mood: Does Entrada Therapeutics Inc have declining or rising EPS2026 AllTime Highs & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Entrada Therapeutics : Corporate Presentation April 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
Is Entrada Therapeutics (TRDA) Stock Undervalued Now | Price at $13.32, Up 1.32%Fundamentals - Newser
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Hedge Fund Bets: Can Entrada Therapeutics Inc outperform under higher oil prices2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
Gainers Report: Can Entrada Therapeutics Inc ride the EV wave2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc benefiting from innovation trends2026 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
0.14%
0.48%
자본화:
|
볼륨(24시간):